Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A; INOVATYON study group. Colombo N, et al. Among authors: rubio perez mj. Br J Cancer. 2023 Apr;128(8):1503-1513. doi: 10.1038/s41416-022-02108-7. Epub 2023 Feb 9. Br J Cancer. 2023. PMID: 36759720 Free PMC article. Clinical Trial.
Paracetamol-induced fixed drug eruption at an unusual site.
Gómez-Traseira C, Rojas-Pérez-Ezquerra P, Sánchez-Morillas L, González-Mendiola R, Rubio-Pérez M, Moral-Morales A, Juliolaguna-Martinez J. Gómez-Traseira C, et al. Recent Pat Inflamm Allergy Drug Discov. 2013 Sep;7(3):268-70. doi: 10.2174/1872213x113079990018. Recent Pat Inflamm Allergy Drug Discov. 2013. PMID: 23889091
Bullous allergic contact dermatitis caused by Critonia aromatisans.
Gómez-Fernández C, Ramírez-Marín P, Rubio-Pérez M, Casado-Verrier B, Sendagorta-Cudós E, Velayos-Rodríguez M, Vidaurrázaga-Díaz de Arcaya C. Gómez-Fernández C, et al. Contact Dermatitis. 2011 Jul;65(1):57-8. doi: 10.1111/j.1600-0536.2011.01918.x. Contact Dermatitis. 2011. PMID: 21658063 No abstract available.
Allergic reaction to undeclared lupin in a chocolate.
Eguíluz Gracia I, Martínez González de Lema B, Rubio-Pérez M, Ruíz-Giménez L, Recio Blázquez L, Pastor-Vargas C, Fernández-Rivas M. Eguíluz Gracia I, et al. J Investig Allergol Clin Immunol. 2015;25(2):140-2. J Investig Allergol Clin Immunol. 2015. PMID: 25997311 Free article. No abstract available.
Cinitapride-induced exanthema.
González Gutiérrez ML, Rubio Pérez M, Vázquez Cortés S, Martínez González de Lema B. González Gutiérrez ML, et al. J Investig Allergol Clin Immunol. 2010;20(2):174. J Investig Allergol Clin Immunol. 2010. PMID: 20461977 Free article. No abstract available.
[Recurrent signet-ring cell gastric carcinoma evidenced by FDG-PET].
Ruiz-Hernández G, Delgado-Bolton RC, Rubio-Pérez MJ, Jiménez-Vicioso A, Pérez-Castejón MJ, Carreras-Delgado JL. Ruiz-Hernández G, et al. Rev Esp Med Nucl. 2005 Sep-Oct;24(5):326-30. doi: 10.1157/13079285. Rev Esp Med Nucl. 2005. PMID: 16194466 Spanish.
Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Garcia Garcia Y, de Juan Ferré A, Mendiola C, Barretina-Ginesta MP, Gaba Garcia L, Santaballa Bertrán A, Bover Barcelo I, Gil-Martin M, Manzano A, Rubio Pérez MJ, Romeo Marin M, Arqueros Núñez C, García-Martínez E, Gonzalez Martin A. Garcia Garcia Y, et al. Int J Gynecol Cancer. 2019 Jul;29(6):1050-1056. doi: 10.1136/ijgc-2019-000256. Int J Gynecol Cancer. 2019. PMID: 31263024 Clinical Trial.
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators. González-Martín A, et al. N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28. N Engl J Med. 2019. PMID: 31562799 Clinical Trial.
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
Vergote I, Ray-Coquard I, Anderson DM, Cantuaria G, Colombo N, Garnier-Tixidre C, Gilbert L, Harter P, Hettle R, Lorusso D, Mäenpää J, Marth C, Matsumoto K, Ouwens M, Poveda A, Raspagliesi F, Rhodes K, Rubio Pérez MJ, Shapira-Frommer R, Shikama A, Sikorska M, Moore K, DiSilvestro P. Vergote I, et al. Among authors: rubio perez mj. Eur J Cancer. 2021 Nov;157:415-423. doi: 10.1016/j.ejca.2021.08.023. Epub 2021 Sep 28. Eur J Cancer. 2021. PMID: 34597975 Free article. Clinical Trial.
25 results